OverviewSuggest Edit

Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates with the potential to improve the lives of patients and their families. Its mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system.
TypePrivate
Founded2014
HQBasel, CH
Websiteroivant.com

Latest Updates

Employees (est.) (Sep 2019)308(-1%)
Job Openings19

Key People/Management at Roivant Sciences

Vivek Ramaswamy

Vivek Ramaswamy

Founder & CEO
Mayukh Sukhatme

Mayukh Sukhatme

President, Roivant Pharma
Myrtle Potter

Myrtle Potter

Vant Operating Chair, Roivant Pharma
Frank Torti

Frank Torti

Vant Investment Chair, Roivant Pharma
Adele Gulfo

Adele Gulfo

Chief of Commercial Development, Roivant Pharma
Sam Azoulay

Sam Azoulay

Chief Medical Officer, Roivant Pharma
Show more

Roivant Sciences Office Locations

Roivant Sciences has offices in Basel, Cambridge, Durham, Brisbane and in 1 other location
Basel, CH (HQ)
71 Aeschenvorstadt
Basel, CH
8 Viaduktstrasse
Brisbane, US
2000 Sierra Point Pkwy
Cambridge, US
90 Broadway
Cambridge, US
90 Broadway #204
Durham, US
324 Blackwell St
Show all (8)

Roivant Sciences Financials and Metrics

Summary Metrics

Founding Date

2014

Roivant Sciences total Funding

$1.9 b

Roivant Sciences latest funding size

$200 m

Time since last funding

10 months ago

Roivant Sciences investors

Roivant Sciences's latest funding round in November 2018 was reported to be $200 m. In total, Roivant Sciences has raised $1.9 b. Roivant Sciences's latest valuation is reported to be $7 b.
View all funding rounds

Roivant Sciences Revenue

Market valuation

7.0b
Show all financial metrics

Roivant Sciences Online and Social Media Presence

Embed Graph

Roivant Sciences News and Updates

Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL200

BASEL, Switzerland, Nov. 19, 2018 /PRNewswire/ -- Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic-resistant...

Roivant Sciences Announces $200 Million Investment Round

BASEL, Switzerland and LONDON, Nov. 13, 2018 /PRNewswire/ -- Roivant Sciences today announced a $200 million equity financing. New investors include NovaQuest Capital Management, RTW Investments, and other large institutional asset managers. These new investors comprise a majority of the...

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

Roivant Sciences Frequently Asked Questions

  • When was Roivant Sciences founded?

    Roivant Sciences was founded in 2014.

  • Who are Roivant Sciences key executives?

    Roivant Sciences's key executives are Vivek Ramaswamy, Mayukh Sukhatme and Myrtle Potter.

  • How many employees does Roivant Sciences have?

    Roivant Sciences has 308 employees.

  • Who are Roivant Sciences competitors?

    Competitors of Roivant Sciences include Amphivena Therapeutics, Foghorn Therapeutics and Expedeon.

  • Where is Roivant Sciences headquarters?

    Roivant Sciences headquarters is located at 71 Aeschenvorstadt, Basel.

  • Where are Roivant Sciences offices?

    Roivant Sciences has offices in Basel, Cambridge, Durham, Brisbane and in 1 other location.

  • How many offices does Roivant Sciences have?

    Roivant Sciences has 8 offices.